All News

Filter By Year

Product Launch: Quick-Neuron™ Precursor-Human iPSC-derived Neural Precursor Cells
April 29, 2021

Our Quick-Neuron™ Precursor – Human iPSC-derived Neural Precursor Cells (NPCs) proliferate and express a variety of NPC markers, such as neuroectodermal stem cell marker, Nestin (NES) and Vimentin (VIM). • Available from multiple healthy and patient iPSC lines • Proprietary transcription factor-based stem cell differentiation • No genetic footprint • Viable long-term • Suitable for […]

Introducing the Enhanced: Quick-Neuron™ GABAergic – mRNA Kit
April 14, 2021

The Quick-Neuron™ GABAergic – mRNA Kit (Small) facilitates rapid and efficient differentiation of human iPS or ES cells into a population of primarily GABAergic neurons. Quick-Neuron™ GABAergic differentiated cell cultures display typical neurite outgrowth and express a variety of neuronal markers, such as the pan-neuronal marker tubulin beta 3 class III (TUBB3) and the GABAergic […]

Product Launch: Quick-Endothelium™ Vascular – mRNA Kit
February 25, 2021

The Quick-Endothelium™ Vascular – mRNA Kit (Small) facilitates rapid and efficient differentiation of human iPS or ES cells into vascular endothelial cells. Cell cultures display typical endothelial morphology and capillary tube formation, and express the endothelial cell markers cluster of differentiation 31 (CD31) and von Willebrand factor (vWF) as well as the tight junction marker […]

Application Note: Genetic and Functional Profiling of hiPSC-derived Excitatory Neurons Differentiated by Quick-Neuron™ Technology
January 8, 2021
Human induced pluripotent stem cells (hiPSCs) hold much promise in providing unique opportunities to advance the understanding and treatment of human disease. hiPSCs can be expanded in culture indefinitely and can be differentiated into cells of all types, thereby providing a valuable source of trillions of reproducible cells for extended research. In our Application Note [...]
Elixirgen Webinar on Accelerating Drug Discovery with Rapid iPSC Differentiation Technology
October 13, 2020

Elixirgen Scientific’s Director of Molecular Biology Tetsuya Tanaka, Ph.D. webinar presented at the 2020 BIO Innovation Conference on accelerating drug discovery with our rapid iPSC differentiation technology.

Elixirgen Scientific Signs Master Service Agreement with Otsuka Pharmaceuticals
August 28, 2020

TOKYO/BALTIMORE, Aug. 28, 2020 – Elixirgen Scientific announced today that it has entered into a master service agreement (MSA) with Otsuka Pharmaceuticals. Elixirgen Scientific provides Otsuka Pharmaceuticals with its proprietary Quick-Tissue™ differentiation technology that enables rapid and highly efficient differentiation of human induced pluripotent stem cells (hiPSCs) for deeper understanding on human disease biology in […]

Elixirgen Scientific Opens Japan Office and Strengthens Partnership with Ricoh
February 13, 2020

Elixirgen Scientific, Inc. is pleased to announce the opening of a new Japanese office located  in Kawasaki city, Kanagawa Prefecture. The Japan office will allow Elixirgen Scientific to support a growing demand for induced pluripotent stem cell (iPSC) differentiation technologies in Japan and throughout the Asia/Pacific region. This is an important milestone as it is the […]

Application Protocols: Culturing human iPSC-derived mixed neurons on multielectrode arrays
December 18, 2019

The Axion BioSystems Maestro and MED64 Presto multielectrode array (MEA) platforms enable label-free measurement of electrical activity of single cells or cellular networks. A key advantage of these MEA platforms is that cell excitability can be tracked in real-time and over the course of hours, weeks, or months using the same population of cells. Our […]